Does the media favor ANIP or ADMA?

In the previous week, ANI Pharmaceuticals had 17 more articles in the media than ADMA Biologics. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 6 mentions for ADMA Biologics. ANI Pharmaceuticals' average media sentiment score of 0.83 beat ADMA Biologics' score of 0.42 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 14 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive ADMA Biologics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ANIP or ANVS?

In the previous week, ANI Pharmaceuticals had 19 more articles in the media than Annovis Bio. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 4 mentions for Annovis Bio. ANI Pharmaceuticals' average media sentiment score of 0.83 beat Annovis Bio's score of 0.62 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 14 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, LQDA or ANIP?

ANI Pharmaceuticals has higher revenue and earnings than Liquidia. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 39.73 -$68.92M $1.37 51.29 ANI Pharmaceuticals $883.37M 1.93 $78.34M $4.64 15.98

Does the media prefer LQDA or ANIP?

In the previous week, ANI Pharmaceuticals had 8 more articles in the media than Liquidia. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 15 mentions for Liquidia. ANI Pharmaceuticals' average media sentiment score of 0.83 beat Liquidia's score of 0.53 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 14 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Which has stronger earnings and valuation, LNTH or ANIP?

Lantheus has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.27 $233.56M $4.14 24.35 ANI Pharmaceuticals $883.37M 1.93 $78.34M $4.64 15.98

Does the media prefer LNTH or ANIP?

In the previous week, ANI Pharmaceuticals had 14 more articles in the media than Lantheus. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 9 mentions for Lantheus. Lantheus' average media sentiment score of 1.28 beat ANI Pharmaceuticals' score of 0.83 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 14 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media favor BLTE or ANIP?

In the previous week, ANI Pharmaceuticals had 19 more articles in the media than Belite Bio. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 4 mentions for Belite Bio. ANI Pharmaceuticals' average media sentiment score of 0.83 beat Belite Bio's score of -0.75 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative ANI Pharmaceuticals 14 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

ANI Pharmaceuticals (ANIP) Competitors

$74.17 -1.18 (-1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$74.16 -0.02 (-0.02%)

As of 06:01 PM Eastern

Compare

ANIP vs. ADMA, ANVS, LQDA, LNTH, and BLTE

Should you buy ANI Pharmaceuticals stock or one of its competitors? ANI Pharmaceuticals's main competitors and comparable companies include ADMA Biologics (ADMA), Annovis Bio (ANVS), Liquidia (LQDA), Lantheus (LNTH), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does ANI Pharmaceuticals compare to ADMA Biologics?

ANI Pharmaceuticals (NASDAQ:ANIP) and ADMA Biologics (NASDAQ:ADMA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

ANI Pharmaceuticals presently has a consensus price target of $105.83, suggesting a potential upside of 42.69%. ADMA Biologics has a consensus price target of $18.67, suggesting a potential upside of 95.46%. Given ADMA Biologics' higher probable upside, analysts clearly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, ANI Pharmaceuticals had 17 more articles in the media than ADMA Biologics. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 6 mentions for ADMA Biologics. ANI Pharmaceuticals' average media sentiment score of 0.83 beat ADMA Biologics' score of 0.42 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	14 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
ADMA Biologics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has lower revenue, but higher earnings than ANI Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.93	$78.34M	$4.64	15.98
ADMA Biologics	$510.17M	4.19	$146.93M	$0.70	13.64

ANI Pharmaceuticals has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

ADMA Biologics has a net margin of 32.98% compared to ANI Pharmaceuticals' net margin of 11.07%. ADMA Biologics' return on equity of 40.17% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
ADMA Biologics	32.98%	40.17%	26.97%

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

ANI Pharmaceuticals beats ADMA Biologics on 9 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Annovis Bio?

ANI Pharmaceuticals (NASDAQ:ANIP) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

ANI Pharmaceuticals presently has a consensus price target of $105.83, suggesting a potential upside of 42.69%. Annovis Bio has a consensus price target of $11.67, suggesting a potential upside of 568.58%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, ANI Pharmaceuticals had 19 more articles in the media than Annovis Bio. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 4 mentions for Annovis Bio. ANI Pharmaceuticals' average media sentiment score of 0.83 beat Annovis Bio's score of 0.62 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	14 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.93	$78.34M	$4.64	15.98
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

ANI Pharmaceuticals has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

ANI Pharmaceuticals has a net margin of 11.07% compared to Annovis Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Annovis Bio	N/A	-685.98%	-258.77%

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

ANI Pharmaceuticals beats Annovis Bio on 11 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Liquidia?

Liquidia (NASDAQ:LQDA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

In the previous week, ANI Pharmaceuticals had 8 more articles in the media than Liquidia. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 15 mentions for Liquidia. ANI Pharmaceuticals' average media sentiment score of 0.83 beat Liquidia's score of 0.53 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	14 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Liquidia has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Liquidia currently has a consensus price target of $98.08, suggesting a potential upside of 39.58%. ANI Pharmaceuticals has a consensus price target of $105.83, suggesting a potential upside of 42.69%. Given ANI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

ANI Pharmaceuticals has higher revenue and earnings than Liquidia. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	39.73	-$68.92M	$1.37	51.29
ANI Pharmaceuticals	$883.37M	1.93	$78.34M	$4.64	15.98

Liquidia has a net margin of 30.74% compared to ANI Pharmaceuticals' net margin of 11.07%. Liquidia's return on equity of 149.65% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

Summary

Liquidia beats ANI Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Lantheus?

Lantheus (NASDAQ:LNTH) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lantheus has a net margin of 17.69% compared to ANI Pharmaceuticals' net margin of 11.07%. Lantheus' return on equity of 28.10% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

In the previous week, ANI Pharmaceuticals had 14 more articles in the media than Lantheus. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 9 mentions for Lantheus. Lantheus' average media sentiment score of 1.28 beat ANI Pharmaceuticals' score of 0.83 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	14 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.35
ANI Pharmaceuticals	$883.37M	1.93	$78.34M	$4.64	15.98

Lantheus presently has a consensus target price of $108.11, suggesting a potential upside of 7.25%. ANI Pharmaceuticals has a consensus target price of $105.83, suggesting a potential upside of 42.69%. Given ANI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Summary

Lantheus beats ANI Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Belite Bio currently has a consensus price target of $205.80, indicating a potential upside of 29.54%. ANI Pharmaceuticals has a consensus price target of $105.83, indicating a potential upside of 42.69%. Given ANI Pharmaceuticals' higher possible upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Belite Bio has a beta of -1.22, suggesting that its stock price is 222% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ANI Pharmaceuticals has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
ANI Pharmaceuticals	$883.37M	1.93	$78.34M	$4.64	15.98

ANI Pharmaceuticals has a net margin of 11.07% compared to Belite Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

In the previous week, ANI Pharmaceuticals had 19 more articles in the media than Belite Bio. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 4 mentions for Belite Bio. ANI Pharmaceuticals' average media sentiment score of 0.83 beat Belite Bio's score of -0.75 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
ANI Pharmaceuticals	14 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

ANI Pharmaceuticals beats Belite Bio on 12 of the 15 factors compared between the two stocks.

Get ANI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIP vs. The Competition

Export

Metric	ANI Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.73B	$12.53B	$7.36B	$12.81B
Dividend Yield	N/A	2.61%	2.53%	10.78%
P/E Ratio	15.98	780.42	270.55	24.05
Price / Sales	1.93	754.07	630.76	95.90
Price / Cash	7.58	15.47	29.03	36.89
Price / Book	3.09	10.42	11.18	6.40
Net Income	$78.34M	$2.79B	$3.46B	$347.95M
7 Day Performance	-2.41%	2.25%	1.98%	0.91%
1 Month Performance	-4.48%	4.72%	7.32%	5.10%
1 Year Performance	-18.50%	7.07%	24.76%	16.16%

ANI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIP ANI Pharmaceuticals	4.319 of 5 stars	$74.17 -1.6%	$105.83 +42.7%	-17.2%	$1.73B	$883.37M	15.98	600
ADMA ADMA Biologics	3.9379 of 5 stars	$9.34 -1.4%	$18.67 +99.9%	-44.7%	$2.12B	$510.17M	13.34	530
ANVS Annovis Bio	3.164 of 5 stars	$1.76 -4.9%	$11.67 +562.9%	-24.0%	$64.10M	N/A	N/A	3
LQDA Liquidia	4.2706 of 5 stars	$77.70 +4.4%	$98.08 +26.2%	+155.7%	$6.66B	$450.91M	56.72	50	Insider Trade
LNTH Lantheus	3.3101 of 5 stars	$100.91 0.0%	$108.11 +7.1%	+71.7%	$6.59B	$1.54B	24.37	1,193	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIP) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, LQDA, LNTH, and BLTE

How does ANI Pharmaceuticals compare to ADMA Biologics?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Summary

How does ANI Pharmaceuticals compare to Liquidia?

Summary

How does ANI Pharmaceuticals compare to Lantheus?

Summary

How does ANI Pharmaceuticals compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, LQDA, LNTH, and BLTE

How does ANI Pharmaceuticals compare to ADMA Biologics?

Do analysts rate ANIP or ADMA?

Does the media favor ANIP or ADMA?

Which has stronger earnings & valuation, ANIP or ADMA?

Which has more volatility and risk, ANIP or ADMA?

Is ANIP or ADMA more profitable?

Do institutionals and insiders hold more shares of ANIP or ADMA?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Do analysts rate ANIP or ANVS?

Does the media favor ANIP or ANVS?

Which has stronger earnings & valuation, ANIP or ANVS?

Which has more volatility and risk, ANIP or ANVS?

Is ANIP or ANVS more profitable?

Do institutionals and insiders hold more shares of ANIP or ANVS?

Summary

How does ANI Pharmaceuticals compare to Liquidia?

Does the media prefer LQDA or ANIP?

Do institutionals and insiders have more ownership in LQDA or ANIP?

Which has more risk and volatility, LQDA or ANIP?

Do analysts rate LQDA or ANIP?

Which has stronger earnings and valuation, LQDA or ANIP?

Is LQDA or ANIP more profitable?

Summary

How does ANI Pharmaceuticals compare to Lantheus?

Do insiders and institutionals hold more shares of LNTH or ANIP?

Is LNTH or ANIP more profitable?

Does the media prefer LNTH or ANIP?

Which has stronger earnings and valuation, LNTH or ANIP?

Do analysts prefer LNTH or ANIP?

Which has more risk & volatility, LNTH or ANIP?

Summary

How does ANI Pharmaceuticals compare to Belite Bio?

Do analysts rate BLTE or ANIP?

Which has more risk & volatility, BLTE or ANIP?

Do institutionals & insiders hold more shares of BLTE or ANIP?

Which has higher earnings and valuation, BLTE or ANIP?

Is BLTE or ANIP more profitable?

Does the media favor BLTE or ANIP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools